JBIO
Jade Biosciences, Inc.
NASDAQ: JBIO · HEALTHCARE · BIOTECHNOLOGY
$24.40
+9.32% today
Updated 2026-04-30
Market cap
$1.32B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.19
Dividend yield
—
52W range
$7 – $28
Volume
0.6M
Jade Biosciences, Inc. (JBIO) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | $1000.00 | $15000.00 | $68000.00 | $96000.00 | $282000.00 | $26000.00 |
| Gross profit | $-1000.00 | $-15000.00 | $-68000.00 | $-96000.00 | $-282000.00 | $-26000.00 |
| Gross margin | — | — | — | — | — | — |
| R&D | $7.94M | $14.99M | $38.62M | $64.22M | $53.19M | $93.12M |
| SG&A | — | — | — | — | $8608.00 | $20.42M |
| Operating income | $-8.89M | $-23.02M | $-53.24M | $-81.41M | $-74.60M | $-113.54M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-9.54M | $-22.95M | $-51.42M | $-75.37M | $-69.29M | $-113.54M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-9.54M | $-22.96M | $-51.49M | $-75.47M | $-69.57M | $-113.57M |
| Interest expense | $75000.00 | — | — | — | — | — |
| Income tax | — | $3000.00 | $25000.00 | $56000.00 | $55000.00 | — |
| Effective tax rate | 0.0% | -0.0% | -0.0% | -0.1% | -0.1% | 0.0% |
| Net income | $-9.61M | $-22.96M | $-51.51M | $-75.52M | $-69.63M | $-127.41M |
| Net income growth (YoY) | — | -138.9% | -124.3% | -46.6% | +7.8% | -83.0% |
| Profit margin | — | — | — | — | — | — |